Clinical Trial Update: A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

View source ↗

Summary

Completed trial assessing outcomes of olaparib maintenance monotherapy in newly diagnosed BRCA wild-type ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Ovarian Cancer | Status: COMPLETED